CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
替代性 CAR 疗法：改造嵌合抗原受体免疫细胞以对抗肿瘤的最新方法
英文原题：Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer.
查看英文原题
Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近三十年来，嵌合抗原受体（CAR）一直吸引研究者关注，推动开发癌症新型免疫疗法。CAR最初为T细胞设计，首种CAR-T 细胞疗法于2017年获批用于B细胞淋巴瘤。CAR技术近期进展推动改良型CAR开发，包括多特异性CAR和逻辑门控CAR。此外，研究者还工程化改造自然杀伤（NK）细胞和巨噬细胞等其他免疫细胞，使其表达CAR以治疗癌症。CAR技术也被调整用于自身免疫性疾病及其他病症的新疗法。本文回顾替代型CAR疗法及设计的近期进展、作用机制、应用挑战和未来潜在方向。
展开英文摘要原文
For nearly three decades, chimeric antigen receptors (CARs) have captivated the interest of researchers seeking to find novel immunotherapies to treat cancer. CARs were first designed to work with T cells, and the first CAR T cell therapy was approved to treat B cell lymphoma in 2017. Recent advancements in CAR technology have led to the development of modified CARs, including multi-specific CARs and logic gated CARs. Other immune cell types, including natural killer (NK) cells and macrophages, have also been engineered to express CARs to treat cancer.
Additionally, CAR technology has been adapted in novel approaches to treating autoimmune disease and other conditions and diseases. In this article, we review these recent advancements in alternative CAR therapies and design, as well as their mechanisms of action, challenges in application, and potential future directions.
论文信息
- 作者
- Moreno C、Haynie C、Cheever A、Weber KS
- 单位
- Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA.United States
- 文献类型
- 综述
- 期刊
- Biomedicines2022 Jun 24
- 原文标识
- PubMed 35884798 · DOI 10.3390/biomedicines10071493
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →